Therefore, we set out to gain an in-depth understanding of the molecular mechanisms of acquired Ganetespib resistance in vivo, with the ultimate goal of advancing treatment options and improving outcomes for patients with HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.